Moody Aldrich Partners adds Cambrex Corporation (CBM) to its portfolio

Cambrex Corporation (CBM) : Moody Aldrich Partners added new position in Cambrex Corporation during the most recent quarter end. The investment management firm now holds 20,130 shares of Cambrex Corporation which is valued at $971,071 , the company said in a statement filed on Apr 25, 2016 with the SEC.Cambrex Corporation makes up approximately 2.06% of Moody Aldrich Partners’s portfolio.

Cambrex Corporation opened for trading at $49.45 and hit $51.16 on the upside on Monday, eventually ending the session at $49.21, with a gain of 2.01% or 0.97 points. The heightened volatility saw the trading volume jump to 8,90,222 shares. Company has a market cap of $1,574 M.

Other Hedge Funds, Including , Louisiana State Employees Retirement System boosted its stake in CBM in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 14,100 shares of Cambrex Corporation which is valued at $680,184. Cambrex Corporation makes up approx 0.04% of Louisiana State Employees Retirement System’s portfolio.Metlife Securities Inc boosted its stake in CBM in the latest quarter, The investment management firm added 47 additional shares and now holds a total of 156 shares of Cambrex Corporation which is valued at $7,098.First Quadrant L Pca reduced its stake in CBM by selling 14,900 shares or 22.37% in the most recent quarter. The Hedge Fund company now holds 51,700 shares of CBM which is valued at $2,352,350. Cambrex Corporation makes up approx 0.05% of First Quadrant L Pca’s portfolio. Simplex Trading sold out all of its stake in CBM during the most recent quarter. The investment firm sold 1,615 shares of CBM which is valued $69,736.

On the company’s financial health, Cambrex Corporation reported $0.50 EPS for the quarter, beating the analyst consensus estimate by $ 0.16 according to the earnings call on Apr 29, 2016. Analyst had a consensus of $0.34. The company had revenue of $94.74 million for the quarter, compared to analysts expectations of $82.87 million. The company’s revenue was up 22.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.

Many Wall Street Analysts have commented on Cambrex Corporation. Shares were Reiterated by Singular Research on Feb 11, 2016 to “Buy” and Lowered the Price Target to $ 60 from a previous price target of $63 .Cambrex Corporation was Initiated by Sidoti to “Buy” on Feb 1, 2016.

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.

Leave a Reply

Cambrex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cambrex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.